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H2S protects against fatal myelosuppression
by promoting the generation of
megakaryocytes/platelets
Huan-Di Liu1,2†, Ai-Jie Zhang1†, Jing-Jing Xu1,3, Ying Chen1 and Yi-Chun Zhu1*
Abstract
Background: Our previous pilot studies aimed to examine the role of hydrogen sulfide (H2S) in the generation of
endothelial progenitor cells led to an unexpected result, i.e., H2S promoted the differentiation of certain
hematopoietic stem/progenitor cells in the bone marrow. This gave rise to an idea that H2S might promote
hematopoiesis.
Methods: To test this idea, a mice model of myelosuppression and cultured fetal liver cells were used to examine
the role of H2S in hematopoiesis.
Results: H2S promoted the generation of megakaryocytes, increased platelet levels, ameliorate entorrhagia, and
improved survival. These H2S effects were blocked in both in vivo and in vitro models with thrombopoietin (TPO)
receptor knockout mice (c-mpl−/− mice). In contrast, H2S promoted megakaryocytes/platelets generation in both in
vivo and in vitro models with TPO knockout mice (TPO−/− mice).
Conclusions: H2S is a novel promoter for megakaryopoiesis by acting on the TPO receptors but not TPO to
generate megakaryocytes/platelets.
Keywords: Hydrogen sulfide, Myelosuppression, Hematopoiesis
Background
Serious myelosuppression is one of the fatal diseases
manifested as a suppression on all types of hematopoietic
cells and remains as one of the most difficult diseases to
treat to date. Myelosuppression is either primary includ-
ing aplastic anemia (AA) and myelodysplastic syndrome
(MDS) or secondary to various disease status including
chemotherapy and accidental/therapeutic radiation ex-
posure [1–3]. Among the severe complications of mye-
losuppression, thrombocytopenia is immediately life
threatening. Platelet transfusion is currently applied to
treat severe thrombocytopenia; however, it has various
side effects being common with the transfusion of
blood components, and the endogenous generation of
platelet is not ameliorated with such therapy [4, 5]. A
more etiological treatment is the administration of re-
combinant thrombopoietin (TPO) which exerts signifi-
cant effects in promoting platelet generation; however,
it also has some side effects such as induction of auto-
antibodies due to the cross-reactions with endogenous
TPO [4, 6, 7]. Since the effects of TPO receptor ago-
nists are mild [6, 8, 9], exploration for new approaches
to treat severe myelosuppression has potential transla-
tional values.
TPO has been established as a main cytokine to pro-
mote the generation of megakaryocytes and platelets by
acting on its receptor, c-mpl [10–12]. The most estab-
lished role of TPO is to promote the generation and dif-
ferentiation of the hematopoietic stem cells in the bone
marrow by acting on the TPO receptors, particularly the
megakaryocytic stem/progenitor cells differentiated to
megakaryocytes [13–15]. The TPO receptors are also
found in the leukocytic and erythrocytic hematopoietic
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stem cells to be involved in the generation of leukocytes
and erythrocytes in adulthood bone marrow [14, 16, 17].
Hydrogen sulfide (H2S) is endogenously generated
in mammals via the H2S-generating enzymes cystathio-
nine γ-lyase (CSE), cystathionine β-synthase (CBS), and 3-
mercaptopyruvate sulfurtransferase (3-MST) [18–20]. H2S
was considered as a metabolite without any physiological
roles at the very start. The first piece of evidence reflecting
a physiological role of H2S was found in organ bath exper-
iments where an H2S donor, sodium hydrosulfide (NaHS),
caused relaxation of the isolated vessels [21]. In the fol-
lowing years, H2S has been found to regulate the function
of the cardiovascular system [22–24], the nervous system
[25–27], the endocrine system [28, 29], and the immune
system [30–32], among which the cardiovascular role of
H2S is the most well established, including a regulation of
vascular tone [33, 34] and remodeling [35–37], a protec-
tion against ischemia/reperfusion injury of the cardiomyo-
cytes and myocardium [38, 39], regulation of ion channels
[22, 40], and promotion of angiogenesis [41–43]. To date,
any potential role of H2S in hematopoiesis is unknown.
Here, we report a novel protective effect of the gas
molecule, H2S, against fatal myelosuppression being
dependent on c-mpl. This is an unexpected finding in
our studies investigating the role of endothelial progeni-
tor cells in the proangiogenic effects of H2S which we
found previously [41, 44, 45]. Though our data showed
that the endothelial progenitor cells were not involved in
these H2S effects, these pilot experiments revealed a
novel promoting effect of H2S on hematopoiesis. This
prompts us to propose a hypothesis that H2S may ameli-
orate myelosuppression.
In the present study, an H2S donor (NaHS) was applied
to treat fatal myelosuppression in a mice model exposed
to radiation and this is the first effort to examine the role
of the gas transmitter H2S on hematopoiesis.
Results
H2S promotes megakaryocytes/platelets generation,
alleviates bleeding, and improves survival in WT mice
with radiation-induced myelosuppression
Exposure to radiation caused significant arrest of the
bone marrow evidenced with a decrease in platelet levels
in days 7, 14 and 21 in a mice model. The eliminating
effect of radiation on circulating platelets peaked at days
7 and 14. Circulating platelet levels rebounded to control
levels at day 28 and remained stable afterwards (Fig. 1a).
Treatment with NaHS caused a significant increase in
platelet levels at day 7 at dosages of 100 and
150 μmol kg−1 day−1 as compared with the vehicle-
treated mice with radiation-induced myelosuppression
(Fig. 1b). TPO treatment (15 μg kg−1) also increased
platelet levels at day 7 (Fig. 1b). Morphological examin-
ation showed that NaHS treatment (100 μmol kg−1 day−1)
significantly increased the number of megakaryocytes in
the bone marrow of the mice exposed to radiation at day
7 (Fig. 1c). Bleeding time was approximately sixfold longer
in the mice exposed to radiation at day 7, and NaHS treat-
ment (100 μmol kg−1 day−1) significantly decreased bleed-
ing time in the mice exposed to radiation (Fig. 1d).
Likewise, fecal occult blood was significantly increased in
the mice exposed to radiation as compared with those in
the controls without exposure to radiation. NaHS treat-
ment (100 μmol kg−1 day−1) significantly decreased fecal
occult blood in the mice exposed to radiation (Fig. 1e).
Plasma TPO levels were dramatically increased after radi-
ation exposure; however, they were not changed by NaHS
treatment (100 μmol kg−1 day−1) (Fig. 1f). Radiation ex-
posure caused a mortality rate of 58 and 71 % at day 14
and day 21, respectively. Mortality did not further increase
after day 28 in all groups. Survival was significantly in-
creased in the mice treated with NaHS at a dosage of
100 μmol kg−1 day−1 at days 14, 21, 28, 35, and 42 after ra-
diation exposure (P < 0.05 vs the vehicle-treated group)
(Fig. 1g). TPO treatment (15 μg kg−1) also caused a signifi-
cant increase in survival (Fig. 1g). On the other hand,
endogenous H2S generation might be decreased after radi-
ation exposure, since we found decreased plasma H2S
levels after radiation exposure at day 7 (Fig. 1h), whereas
NaHS treatment (100 μmol kg−1 day−1) recovered plasma
H2S to a level comparable to that in the mice without ra-
diation exposure (Fig. 1h).
H2S promotes differentiation of the hematopoietic stem
cells into megakaryocytes
To investigate if the abovementioned in vivo effect of
H2S resulted from a stimulation on the hematopoietic
stem cells, the potential effect of H2S on the differenti-
ation of the hematopoietic stem cells into megakaryo-
cytes was examined with flow cytometry where CD61
was used as the surface molecular marker for the mega-
karyocyte (Fig. 2a). These cells were further examined
with confocal microscopy with double-staining using
fluorescent-labeled antibodies against CD41 (green) and
CD61 (red) where these two markers were co-localized
on the cell membrane (Fig. 2c). This is in accordance
with the literature that both CD41 and CD61 are
expressed on the cell membrane of mature megakaryo-
cytes. Since the hematopoietic stem cells are originally
generated in fetal liver at the 11.5 day during the embry-
onic period (E11.5) and then expand at E14.5 before mi-
gration to the bone marrow [46, 47], we harvested the
E14 fetal liver cells which were rich in hematopoietic
stem cells to examine the in vitro effect of H2S in the
present study. NaHS treatment concentration depend-
ently promoted differentiation of cultured fetal liver cells
into the megakaryocytes at 10, 20, 50, and 100 μmol L−1
as examined with flow cytometry (Fig. 2a). Platelet
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generation was also increased in the cultured fetal liver
cells treated with NaHS at concentrations of 50 and
100 μmol L−1 examined with flow cytometry defined as
CD41-positive and 7-AAD-negative signals, respectively
(Fig. 2b). H2S-induced increase in megakaryocyte gener-
ation at a concentration of 100 μmol L−1 was even
higher than that induced by TPO at 10 ng mL−1 (Fig. 2a),
whereas TPO treatment (10 ng mL−1) showed a more
significant effect in promoting platelet generation than
NaHS treatment (100 μmol L−1) (Fig. 2b). Scanning elec-
tron microscopy showed the morphology of the mega-
karyocytes where pseudopod formation (blue arrow) and
membrane blebbing (yellow arrow head) were observed
in the cells treated with NaHS (Fig. 2d).
c-mpl is required for H2S to promote megakaryocytes/
platelets generation and improve survival
To further clarify how H2S can promote megakaryocytes
generation and provide protection against fatal myelo-
suppression, some knockout mice models were applied.
TPO has a pivotal role in the generation of megakaryocytes
and platelets by acting on its receptor, c-mpl [10–12]. The
data showed that platelet count was decreased by about
80 % in c-mpl−/− mice as compared with that in wild-type
(WT) mice (Fig. 3a). NaHS treatment (20 μmol kg−1 day−1)
for 14 days caused an increase in circulating platelet levels
in WT mice but not in c-mpl−/− mice (Fig. 3a). Likewise,
NaHS treatment promoted the generation of megakaryo-
cytes in the fetal liver cells isolated from WT mice at con-
centrations ranging from 10 to 100 μmol L−1 (Fig. 2a) but
not in the fetal liver cells isolated from the c-mpl−/− mice
(Fig. 3b). Circulating platelet levels were significantly de-
creased in c-mpl−/− mice as compared with those of the
WT mice. Radiation exposure caused significant decrease
in circulating platelet levels in both WT and c-mpl−/−
mice, and this decrease was partially recovered with NaHS
treatment (100 μmol kg−1 day−1) in WT mice but not in
c-mpl−/− mice (Fig. 3c). Likewise, NaHS treatment in-
creased megakaryocyte levels in the bone marrow in WT
mice exposed to radiation (Fig. 1c) but not in those of the
c-mpl−/− mice (Fig. 3d). Bleeding time (Fig. 3e) and fecal
occult blood (Fig. 3f ) were not ameliorated by NaHS
treatment (100 μmol kg−1 day−1) in the c-mpl−/− mice
exposed to radiation at day 7, though these parameters
were improved in the WT mice by NaHS treatment
(100 μmol kg−1 day−1) (Fig. 1d, e). Finally, NaHS treat-
ment (100 μmol kg−1 day−1) improved survival after ra-
diation exposure in WT mice (Fig. 1g) but not in c-mpl−/−
mice (Fig. 3g).
The role of TPO in H2S-induced promotion on
megakaryocytes/platelets generation
On the other hand, TPO is the main cytokine to pro-
mote the production of megakaryocytes and platelets [11,
48, 49]. Though plasma TPO levels were not increased
by H2S treatment in WT mice exposed to radiation
(Fig. 1f ), the role of TPO in mediating the hematopoietic
effects of H2S was still worthy to be investigated. There-
fore, the potential hematopoietic effects of H2S were also
examined in TPO−/− mice with or without radiation ex-
posure and in the fetal liver cells isolated from the TPO−/−
mice. TPO knockout caused about 90 % reduction in cir-
culating platelet levels in mice without radiation exposure
(Fig. 4a). NaHS treatment (20 μmol kg−1 day−1) for 14 days
caused about a 43 % increase in circulating platelet levels
in TPO−/− mice (Fig. 4a). Megakaryocyte generation was
promoted with NaHS treatment (100 μmol L−1) in fetal
liver cells isolated from the TPO−/− mice, and this effect
was more pronounced than that with exogenous TPO
treatment (10 ng mL−1) (Fig. 4b). Radiation exposure
caused a significant decrease in circulating platelet levels
in both WT mice and TPO−/− mice (Fig. 4c). NaHS treat-
ment (100 μmol kg−1 day−1) increased circulating platelet
levels in both WT mice and TPO−/− mice exposed to radi-
ation (Fig. 4c), whereas this H2S effect in TPO
−/− mice
was less pronounced than that in WT mice (Fig. 4d).
However, NaHS treatment (100 μmol kg−1 day−1) did not
cause a significant increase in megakaryocyte levels in the
(See figure on previous page.)
Fig. 1 H2S treatment promotes platelet generation, alleviates bleeding, and improves survival in WT mice with radiation-induced myelosuppression. a Time
course of circulating platelet counts after exposure to radiation of 137Cs at a single dose of 7.5 Gy. b NaHS treatment caused a significant increase in
circulating platelet levels at 100 and 150 μmol kg−1 day−1 on day 7 after radiation exposure. TPO treatment also provided a similar amelioration at
15 μg kg−1. c Morphological examination showed a significant decrease in the number of megakaryocytes (black arrow) in the bone marrow of WT mice
exposed to radiation, whereas NaHS (100 μmol kg−1 day−1) significantly increased the number of megakaryocytes as compared with the vehicle-treated
group. Scale bar = 250 μm. d Bleeding time was prolonged after exposure to radiation, and bleeding was ameliorated by NaHS treatment (100 μmol kg
−1 day−1) as compared with that of vehicle-treated WT mice. e Likewise, fecal occult blood was significantly increased after exposure to radiation and NaHS
treatment (100 μmol kg−1 day−1) caused a significant decrease in fecal occult blood in mice exposed to radiation. f Plasma TPO concentrations were
increased in WT mice on day 7 after radiation exposure where NaHS treatment (100 μmol kg−1 day−1) did not change TPO concentrations. g Radiation
exposure resulted in a significant decrease in survival as compared with that of the mice without radiation exposure. Both NaHS (100 μmol kg−1 day−1)
and TPO (15 μg kg−1) treatment significantly improved survival in these mice exposed to radiation. *P< 0.05, **P< 0.01 versus vehicle-treated mice exposed
to radiation, log-rank test. h Plasma H2S levels were decreased in mice exposed to radiation, and this decrease was recovered by administration of NaHS
(100 μmol kg−1 day−1). Data in the graphs are means ± SEM. P values less than 0.05 represent statistical significance
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Fig. 2 H2S treatment promotes generation of megakaryocytes/platelets in cultured fetal liver cells. a NaHS treatment caused a concentration-
dependent increase in megakaryocytes which were identified as CD61-positive cells using flow cytometry in fetal liver cells isolated from WT mice.
b Platelets were identified as CD41-positive and 7-AAD-negative signals using flow cytometry. Platelet counts were significantly increased with
NaHS treatment at 50 and 100 μmol L−1 in the culture medium of fetal liver cells. TPO treatment (10 ng mL−1) also increased platelet counts. c
Morphology of megakaryocytes in cultured fetal liver cells were shown with a confocal fluorescence microscopy with staining of DAPI, CD41-FITC,
and CD61-PE. Scale bar = 50 μm. d Scanning electron microscopy revealed pseudopod formation (blue arrow) and membrane blebbing (yellow arrow)
in the megakaryocytes identified in cultured fetal liver cells treated with NaHS (100 μmol L−1). Data in the graphs are means ± SEM. P values less than
0.05 represent statistical significance
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bone marrow of the TPO−/− mice exposed to radiation
(Fig. 4e). Likewise, NaHS treatment (100 μmol kg−1 day−1)
failed to ameliorate bleeding (Fig. 4f) and fecal occult
blood (Fig. 4g) despite an increase in the circulating plate-
let levels in TPO−/− mice with radiation exposure and
treated with NaHS treatment (100 μmol kg−1 day−1). As a
final consequence, NaHS treatment (100 μmol kg−1 day−1)
did not improve survival in TPO−/− mice exposed to radi-
ation (Fig. 4h) although survival was improved in WT
mice (Fig. 1g).
Discussion
This is the first time that the gas transmitter H2S has
been found to protect against fatal myelosuppression
with improvement in bone marrow morphology, cir-
culating platelet levels, and final survival. The in-
creased survival in H2S-treated mice may be ascribed
to the decreased internal bleeding. This idea was sup-
ported by less bleeding time and fecal occult blood
found in these H2S-treated mice. Moreover, these ef-
fects were found at physiologically relevant dosages of
H2S since the treatment just recovered the decrease
in plasma H2S levels in radiation-exposed mice.
Therefore, these findings have potential translational
values and may be further explored for new ap-
proaches to treat fatal diseases resulting from severe
myelosuppression.
In the embryonic period, hematopoiesis mainly occurs
in the liver where the hematopoietic stem cells were dif-
ferentiated into various types of blood cells [50–52].
Here, we show a novel protective role of H2S in fatal
myelosuppression, i.e., H2S ameliorates internal bleeding
and improves survival by promoting generation of
megakaryocytes and platelets. Future works are re-
quired to further validate this hypothesis using multiple
approaches including bone marrow transplantation
experiments.
We found here that the hematopoietic effects of H2S
were blunted in the c-mpl−/− mice exposed to radiation
and also in the fetal liver cells isolated from the c-mpl−/−
mice. These data suggest that the TPO receptors are
essential for H2S to promote hematopoiesis. In the adult
stage, the TPO receptors are expressed on different mat-
uration stages of megakaryocyte and early hematopoietic
stem/progenitor cells in the bone marrow [53–55]. The
predominant role of the TPO receptors is to mediate the
signals to induce proliferation and differentiation of
megakaryocyte progenitor cells to generate megakaryo-
cytes and platelets [10–12]. In addition, since the TPO
receptors are also expressed on the hematopoietic stem/
progenitor cells, it is also involved in the expansion of
erythroid, granulocyte-macrophage, and megakaryocytic
progenitor cells [14, 16, 17]. Although there are also
some evidence showing expression of the TPO receptors
in the tissues outside of the bone marrow, e.g., in pla-
centa, fetal liver, fetal blood, cord blood, and peripheral
blood, bone marrow is the main place of hematopoiesis
in adulthood [51, 52, 56]. In this context, if the
hematopoietic effect of H2S is dependent on the TPO re-
ceptors, these H2S effects are mediated via the TPO re-
ceptors located in the hematopoietic stem/progenitor
cells in the bone marrow. Indeed, the absence of more
direct evidence using bone marrow transplantation
models is a limitation of our current study.
The mechanisms about how H2S would activate the
TPO receptors are unknown. How a molecule as small
as H2S targets its “receptors” is one of the most challen-
ging questions in the field. Our previous studies aim to
find that the “receptor” of H2S shows that VEGFR2
serves as a direct target molecule for H2S to induce
angiogenesis. The study further shows that H2S targets a
specific molecular switch, i.e., the Cys1024-Cys1045
motif, to regulate the conformation and function of
VEGFR2 by sulfur-sulfur nucleophilic attack [44]. This
suggests a new mechanism beyond the typical docking
between a ligand and its receptor. Some theories of
atomic biology involving molecular orbitals are involved
in this H2S-induced regulation of VEGFR2. Interestingly,
the TPO receptors and VEGFR2 belong to the receptor
tyrosine kinase family. Some members of this kinase
family, e.g., EGFR, have been recently found to contain
an intracellular kinase domain similar to that of the
(See figure on previous page.)
Fig. 3 H2S-induced promotion of megakaryocytes/platelets generation and improvement of survival are blunted in c-mpl
−/− mice. a Without radiation
exposure, NaHS treatment (20 μmol kg−1 day−1) for 14 days caused an increase in circulating platelet levels in WT mice but not in c-mpl−/− mice. b Flow
cytometry showed that NaHS treatment (100 μmol L−1) failed to increase the number of megakaryocytes identified as CD61-positive cells in cultured
fetal liver cells isolated from c-mpl−/− mice. c Circulating platelets were significantly decreased in both WT and c-mpl−/− mice exposed to radiation at
day 7. NaHS treatment (100 μmol kg−1 day−1) increased platelet levels in WT mice but not in c-mpl−/− mice. d Morphological examination of the bone
marrow showed that NaHS treatment (100 μmol kg−1 day−1) failed to increase the number of megakaryocytes (black marrows) in c-mpl−/−
mice. Scale bar = 250 μm. e Bleeding was not ameliorated with NaHS treatment (100 μmol kg−1 day−1) in c-mpl−/− mice exposed to radiation
at day 7. f Likewise, fecal occult blood was not ameliorated with NaHS treatment (100 μmol kg−1 day−1) in c-mpl−/− mice exposed to
radiation at day 7. g NaHS treatment (100 μmol kg−1 day−1) failed to improve survival in c-mpl−/− mice exposed to radiation as compared to
vehicle-treated mice. *P < 0.05 versus vehicle-treated mice exposed to radiation, log-rank test. Data in the graphs are means ± SEM. P values
less than 0.05 represent statistical significance
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VEGFR2 also with a molecular switch labile to H2S
regulation [57]. This gives rise to an idea that the TPO
receptors might also contain a similar intracellular kin-
ase domain with a molecular switch sensitive to H2S
regulation. Indeed, much future works are required to
examine this hypothesis.
In TPO−/− mice exposed to radiation, H2S also failed
to ameliorate internal hemorrhage and improve survival
despite a significant increase in circulating platelet levels.
In addition, H2S promoted megakaryocytes/platelets
generation in cultured fetal liver cells isolated from
TPO−/− mice but not in c-mpl−/− mice. These data suggest
an essential role of the TPO receptor but not TPO for
H2S to promote hematopoiesis. The question is why H2S
increased platelet levels in TPO−/− mice without amelior-
ating bleeding and subsequent mortality? This discrepancy
might be ascribed to a significantly decreased survival in
TPO−/− mice treated with vehicle as compared with that
in c-mpl−/− mice (P < 0.01, Additional file 1: Figure S1).
Myelosuppression might be too severe to be recovered by
H2S in these TPO
−/− mice, whereas the TPO receptors
were present in the cells isolated from the TPO−/− mice
and might serve as a target molecule for H2S to promote
hematopoiesis.
In addition, H2S also increased circulating leukocytes
in WT mice exposed to radiation at day 14 though
erythrocytes were not increased (Additional file 2: Figure
S2). Our present data are not sufficient to clarify
whether such an improvement in circulating leukocyte
counting contributes to an increase in survival in mice
exposed to radiation due to an improvement in the im-
mune system.
Conclusions
Taken together, treatment for fatal myelosuppression is
proven a difficult challenge in medicine. Here, we report
a novel protective role of H2S in a mice model of fatal
myelosuppression. This finding has potential transla-
tional values which could be further explored to develop
new approaches to treat fatal myelosuppression. Moreover,
experiments using the models with knockout of the TPO
receptors or TPO itself indicate that the hematopoietic
effect of H2S is dependent on the TPO receptors but
not on TPO. In addition, the endogenous generation of
H2S was reduced in the myelosuppression model and a
recovery of the H2S levels was associated with a protec-
tion against radiation exposure. These findings shed
some light to uncovering a new mechanism to regulate
hematopoiesis by a gas transmitter, H2S.
Methods
Animals
Wild-type C57BL/6 mice (WT mice) were purchased
from the Department of Laboratory Animal Science of
Fudan University and acclimatized for at least 2 weeks
before experiments. c-mpl is the receptor of TPO; the c-
mpl knockout mice (c-mpl−/− mice) were provided by
The Jackson Laboratory (Bar Harbor, ME, USA) with an
80 % decrease in the number of platelets in comparison
to that of wild-type C57BL/6 mice [58, 59] (the strain
name of these c-mpl−/− mice is C57BL/6J-Mplhlb219/J
with the stock number 005124). Likewise, TPO-deficient
mice (TPO−/− mice) have a >80 % decrease in their
platelets [59, 60]. The embryos of TPO−/− mice were
gifts kindly provided by Dr. Fred de Sauvage (Genentech
Inc., USA) and developed into mice through the Embryo
Recovery Service of The Jackson Laboratory (these
TPO−/−mice were produced by targeted mutation on the
background of C57BL/6J mice; for more details, see de
Sauvage [60]). Both TPO−/− and c-mpl−/− mice were
hybridized with WT mice and then their offspring were
genotyped according to the protocol provided by The
Jackson Laboratory. Homozygote animals were used in
the experiments while heterozygote mice were main-
tained for breeding. Only female mice were used in the
experiments. Mice were given free access to food and
water while housed in a clean environment with appro-
priate temperature and humidity. At the time of experi-
ments, all mice were 6–8 weeks old weighting 18–21 g.
Considering that in the experiment mice will die or suf-
fer severe sickness in the process, we set at least 10 mice
per group at the beginning and repeated the experiment
if necessary. To ensure the reliability of results, mice
were randomly allocated to each group. All procedures
(See figure on previous page.)
Fig. 4 H2S promotes megakaryocytes/platelets generation but does not improve survival in TPO
−/− mice. a Without radiation exposure, NaHS
treatment (20 μmol kg−1 day−1) for 14 days caused an increase in circulating platelet levels in both WT and TPO−/− mice. b NaHS treatment
(100 μmol L−1) increased the number of megakaryocytes identified as CD61-positive cells using flow cytometry in cultured fetal liver cells isolated
from TPO−/− mice. c, d NaHS treatment (100 μmol kg−1 day−1) increased circulating platelet levels on day 7 after radiation exposure in both WT
and TPO−/− mice (c). However, the effects of NaHS treatment (100 μmol kg−1 day−1) in increasing circulating platelet levels were blunted in TPO−/−mice
(d). e Morphological examination of the bone marrow showed that NaHS treatment (100 μmol kg−1 day−1) did not increase the number of
megakaryocytes (black arrows) in the TPO−/− mice exposed to radiation. Scale bar = 250 μm. f Bleeding was not ameliorated with NaHS
treatment (100 μmol kg−1 day−1) in the TPO−/− mice exposed to radiation at day 7. g Likewise, fecal occult blood was not ameliorated with
NaHS treatment (100 μmol kg−1 day−1) in the TPO−/− mice exposed to radiation at day 7. h Survival was not improved with NaHS treatment
(100 μmol kg−1 day−1) in TPO−/− mice exposed to radiation. **P < 0.01 versus vehicle-treated mice exposed to radiation, log-rank test. Data in
the graphs are means ± SEM. P values less than 0.05 represent statistical significance
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were approved by the Institutional Animal Care and
Use Committee, Fudan University Shanghai Medical
College (20120302-098).
Irradiation-induced myelosuppression
The Cs-137 instrument (Gammacell-40, MDS Nordion,
CA) was used as the γ-ray irradiation source in this
study. Six- to 8-week-old mice were either exposed to
7.5 Gy (WT mice) or 5.0 Gy (TPO−/− and c-mpl−/−
mice) cesium (137Cs)-emitted radiation for total body ir-
radiation (TBI) to build up the myelosuppression model.
The TPO−/− and c-mpl−/− mice were more sensitive to
radiation exposure, and the mortality was too high to
perform subsequent experiments in these mice. We per-
formed a pilot study to explore the intensity of radiation
exposure in these mice to cause radiation-induced mye-
losuppression with a mortality within the range that en-
ables the subsequent experiments to be performed. The
results showed 5.0 Gy as the radiation intensity for the
TPO−/− and c-mpl−/− mice.
Platelet counts
Platelet counts were measured by automatic blood cell
analyzer (XN-1000, Sysmex, Kobe, Japan). About 80–
100 μL peripheral blood was obtained from the angular
vein of individual mice then pumped into a 1.5-mL
Eppendorf tube coated with ethylenediaminetetraacetic
acid (EDTA) and mixed immediately. For platelet count-
ing, whole blood was used without any dilution. During
all experiments, every single mouse was sampled at
7-day intervals. Frequency and timing of sampling of
each individual mouse was identical in all types of mice
in this study. In this part, the operator of the automatic
blood analyzer was blinded to the sample groups. Results
were excluded in cases where there was clotting in the
sample.
Bleeding time test
The tails of mice were placed horizontally then ampu-
tated about 3 mm from the tip and immersed into saline
solution pre-warmed and maintained at 37 °C. The time
from severing to cessation of bleeding was recorded as
bleeding time, and the longest observation time was
20 min to avoid over bleeding which frequently occurred
in the TPO−/− and c-mpl−/− mice. Researchers were
blinded to the sample groups.
Fecal occult blood test
A fecal occult blood test kit (Baso, Zhuhai, China) was
used to examine occult gastrointestinal bleeding accord-
ing to protocols provided by the manufacturer. Briefly,
20–30 mg feces were smeared on the window of the test
card then dripped with a drop of developer A (pyrami-
don). After sufficient penetration, a drop of developer B
(alcohol and hydrogen peroxide) was dripped and then
the results were read by comparing with a color card
within 2 min. Researchers were blinded to the sample
groups.
Bone marrow megakaryocytes counts
The femur and tibia were collected from some mice
sacrificed at day 7 during the experimental period. After
fixing in 10 % formaldehyde and dehydrated, the bone
samples were embedded into paraffin, sliced, and stained
with hematoxylin and eosin. The morphology of the
bone marrow was assessed via light microscopy (Leica
DMLB, Leica, Germany), and megakaryocytes were
counted by an observer blinded to the sample groups.
For WT mice, no less than 10 visions were observed in
each sample, whereas for TPO−/− and c-mpl−/− mice the
megakaryocytes were counted throughout the whole
slice of the samples.
Cell culture
Mouse fetal livers were collected at E14, cut to pieces,
digested with 0.125 % Tryspin (Life, Thermo fisher
scientific, Waltham, MA, USA), and then filtered succes-
sively through 200-mesh (pore size, 74 μm) and 400-
mesh (pore size, 37 μm) stainless steel screens. The
yielded cells were cultured in RPMI1640 (Gibco, Thermo
Fisher scientific, Waltham, MA, USA) supplemented
with 10 % FBS (HyClone, Logan, Utah, USA) and incu-
bated at 37 °C in 5 % CO2.
Flow cytometry
Cultured fetal liver cells were stained with PE-CD61
(104308, 1:100, Biolegend, San Diego, CA), FITC-CD41
(13903, 1:200, BioLegend, San Diego, CA), or 7-AAD
viability staining solution (420403, 1:20, BioLegend, San
Diego, CA) according to instructions provided by the
manufacturer. Briefly, about one million cells were col-
lected and resuspended in 100 μL phosphate-buffered
saline (PBS) and then stained with respective antibodies
according to its recommended usage for 30 min at 4 °C.
Then the cells were centrifuged at 1000 rpm for 5 min,
and the supernatant was discarded. Then the cells were
washed in 1 mL PBS twice before being resuspended in
500 μL PBS. FACS analysis was performed with a flow
cytometer (FACSCalibur, BD, USA). More than 10,000
cells were acquired and analyzed by CELLQuest. For
each experiment of this part, fetal liver cells isolated
from at least three individual mice were used and for at
least three repetitions for each group. The operator of
the flow cytometer was blinded to the sample groups.
Administration of H2S and TPO
NaHS (Sigma-Aldrich, St. Louis, MO, USA) was applied
as a donor of H2S [45] in the present study. For the in
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vivo administration, NaHS and recombinant murine
TPO (R&D, NASDAQ, USA) were freshly diluted in
sterile saline or PBS for each administration. A single
dose of TPO (15 μg kg−1) was given by intraperitoneal
injection after radiation exposure whereas NaHS was
injected once a day during the experimental period. For in
vitro experiments, recombinant murine TPO (PeproTech,
NJ, USA) was freshly diluted with cell culture medium and
added to the cultured cells with a single dose of 10 ng mL−1
given at the first day of the experiments. NaHS was
diluted with cell culture medium and added to the
cultured cells every 8 h.
Scanning electron microscopy
Specimen were first double fixed with 2.5 % glutaralde-
hyde and 1 % osmium tetroxide and then gradiently
dehydrated with ethanol followed by dehydration in
HCP-2 critical point dryer (Haitchi, Tokyo, Japan) with
liquid CO2. The dehydrated specimen was coated with
gold palladium and then observed in a JSM-6360LV
scanning electron microscope (JEOL, Tokyo, Japan).
Confocal microscopy
Cultured fetal liver cells were stained with PE-CD61
(12-0611, 1:40, eBioscience, San Diego, CA), FITC-CD41
(11-0411, 1:200, eBioscience, San Diego, CA), and the
DAPI staining solution (C1006, 100 μL, Beyotime, China)
and then examined with a confocal laser scanning
microscope LSM 710 (Zeiss, Jena, Germany).
Measurement of plasma H2S
Plasma H2S levels in some mice were measured according
to a method previously described [61]. The concentrations
were determined using the standard curve generated with
a standard NaHS solution.
Measurement of plasma TPO
Plasma TPO levels in some mice were measured using
the Mouse Thrombopoietin Quantiken ELISA Kit (R&D,
NASDAQ, USA) according to the manufacturer’s
instructions.
Statistical analysis
Results were expressed as the mean ± standard error.
Unless specifically stated, the data show normal distri-
bution. For two groups, independent-sample t test
was used. For more than two groups, statistical ana-
lysis was performed with one-way ANOVA followed
by LSD if the variance is homogeneous or Tamhane’s
T2 test when the variance is not homogeneous. For
the fecal occult blood assay, the data were trans-
formed in rank cases first and then analyzed with
one-way ANOVA as above. Comparisons of mortality
were performed with Kaplan-Meier survival curves, in
which log-rank test was used to evaluate differences
in survival. P < 0.05 was considered as statistically
significant.
Additional files
Additional file 1: Figure S1. Survival analysis of c-mpl−/− and
TPO−/− mice after exposure to radiation and treated with vehicle.
TPO−/− mice after exposure to 5.0 Gy 137Cs then treated with vehicle had a
significantly decreased survival compared with that in c-mpl−/− mice
.**P < 0.01, log-rank test. (PDF 44.1 kb)
Additional file 2: Figure S2. H2S increases circulating leukocytes in
WT mice exposed to radiation. (a) NaHS treatment did not change
circulating erythrocytes at dosages of 10, 20, 50, 100, and 150 μmol kg−1
day−1 in WT mice exposed to radiation at day 7 and day 14. (b) NaHS
treatment increased circulation leukocytes at a dosage of 100 μmol kg−1
day−1 in WT mice exposed to radiation at day 14 but not day 7. Data in
the graphs are means ± SEM. P values less than 0.05 represent statistical
significance. (PDF 311 kb)
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